不补偿性肝硬化研究网络 (UK-CLIF):为英国的肝病学试验建立共识
Helen Crisp1, Oliver Tavabie2, Yvanne Enever3
1UCL Institute for Liver and Digestive Health, London, UK.
NIHR open research
|February 11, 2025
概括
英国慢性肝衰竭网络 (UK-CLIF) 是为了改善肝硬化研究而建立的. 确定的主要障碍包括以患者为中心的材料和临床医生资源,指导未来的研究优先事项.
科学领域:
- 肝病学和胃肠病学 肝病学和胃肠学
- 临床试验管理 临床试验管理
- 医疗保健服务研究 医疗服务研究
背景情况:
- 肝脏疾病,特别是肝硬化,是英国日益增长的死亡原因.
- 英国慢性肝衰竭网络 (UK-CLIF) 是为了解决高患病率或研究不足的领域的研究缺口而启动的.
- 采用了多方利益相关者的方法,以促进在推进肝硬化研究方面的合作.
研究的目的:
- 建立一个推进英国肝硬化研究的网络.
- 通过多方利益相关者的参与,确定肝硬化临床试验的关键障碍和优先事项.
- 在改善肝硬化研究基础设施和研究成果的关键领域达成共识.
主要方法:
- 网络开发通过传播和雪球采样,在线监测.
- 通过使用世界咖啡馆方法和点评投票,促进了面对面的研讨会.
- 对参与者的投入进行主题分析,以确定障碍和研究优先事项.
主要成果:
- 肝硬化临床试验的重大障碍包括需要以患者为中心的材料和临床医生的资源不足.
- 对肝硬化住院护理标准的变化被认为是一个挑战.
- 在研究基础设施,临床因素和未来试验优先事项的优先领域达成共识.
结论:
- 英国-CLIF网络成功地吸引了各种利益相关者参与,以确定肝硬化研究中的关键问题.
- 解决患者需求,加强临床医生支持和标准化住院护理对于改善临床试验交付至关重要.
- 未来的英国-CLIF活动将集中在质量改善和协调肝硬化研究的优先设定伙伴关系上.
相关概念视频
01:16Clinical Trials
8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.5K
01:11Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
386
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
275
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
275
01:23Cirrhosis I: Introduction
32
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
32
01:24Cirrhosis II: Pathophysiology
53
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
53